

ALL Acne Patients 12+

WINLEVI[®] is the **first and only** prescription cream that targets acne hormones for clearer skin.^{12*}

What is WINLEVI cream? WINLEVI (clascoterone) cream 1% is a prescription medicine used on the skin (topical) to treat acne vulgaris in people 12 years of age and older.

*The exact way WINLEVI works on acne is unknown.¹ Models shown are not actual patients.

It is not known if WINLEVI cream is safe and effective in children under 12 years of age.

IMPORTANT PATIENT INFORMATION

The most common side effects of WINLEVI cream include reddening, scaling or dryness, and itching of the skin being treated.

Please see Full Prescribing Information and the Patient Information in the pocket or at WINLEVI.com



CNE HAPPENS

HERE'S HOW IT DEVELOPS


WHAT ARE ACNE HORMONES, ANYWAY?


Diet, stress, oily skin, and hair care products may make acne worse. But they aren't the primary cause.³

Hormone levels fluctuate for both FEMALES and MALES throughout all ages and stages of life.

Certain hormones in the skin, called androgens, can fluctuate and start the acne chain reaction.³⁻⁵







 \rightarrow

DISCOVER THE ACNE TREATMENT THAT WORKS DIFFERENTLY

WINLEVI® is the only topical that targets acne hormones in your skin, reducing sebum and inflammation.



WINLEVI is FDA-approved as safe and effective^{1*}

- The safety of WINLEVI was studied over 12 months.
- The most common reactions were mild skin redness, peeling or dryness, and itching where WINLEVI was applied. These are not all of the possible side effects of WINLEVI.
- Side effects were generally mild to moderate.
- In a study where people applied 6X the prescribed amount of WINLEVI, some patients experienced a disorder where the adrenal gland does not make enough of certain hormones. However, this did not occur in WINLEVI clinical trials with the prescribed twice-daily dosing of one gram.⁷⁴⁰

*The exact way WINLEVI works on acne is unknown.¹

IMPORTANT PATIENT INFORMATION

WINLEVI cream is for use on the skin only (topical). Do not use WINLEVI cream in or on your eyes, mouth, or vagina. Do not use WINLEVI cream for a condition for which it was not prescribed. Do not give WINLEVI cream to other people, even if they have the same symptoms you have. It may harm them.



FOCUS ON RESULTS

In clinical studies, WINLEVI[®] showed improvement in acne at 12 weeks of use ^{1,11}

- ✓ Clear or almost clear skin
- A significant reduction of whiteheads and blackheads
- A noticeable reduction in pus-filled pimples

A noticeable reduction in acne was seen as early as Week 4.

MALE WINLEVI PATIENT





FEMALE WINLEVI PATIENT



ACTUAL PATIENTS FROM WINLEVI CLINICAL TRIAL



Once in the morning

Once in the evening

1. PREP



Before using WINLEVI, gently wash and dry the affected area.

2. APPLY



After the skin is dry, apply a fingertip amount (approximately one gram) in 5-8 dots over the entire affected area. Rub in WINLEVI in a thin, even layer, twice a day.



WINLEVI cream is for use on the skin only (topical) Avoid getting WINLEVI cream in or on your eyes, lips, mouth, corners of nose, or mucous membranes

TIPS

If contact with mucous membranes happens, rinse well with water

Store WINLEVI cream at room temperature



IMPORTANT PATIENT INFORMATION, CONT.

Before using WINLEVI cream, tell your healthcare provider about all of your medical conditions, particularly if you:

- have skin problems, including eczema, cuts or sunburn.
- are pregnant or plan to become pregnant. It is not known if WINLEVI cream will harm your unborn baby
- are breastfeeding or plan to breastfeed. It is not known if WINLEVI cream passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with WINLEVI cream

WHAT ARE THE POSSIBLE SIDE EFFECTS OF WINLEVI CREAM?

WINLEVI cream can cause serious side effects, including:

- **local skin reactions.** WINLEVI cream may cause local skin irritation including itching, burning, skin redness or peeling.
- symptoms of a disorder where the adrenal gland does not make enough of certain hormones (adrenal insufficiency) during treatment with WINLEVI. Your healthcare provider may stop your treatment with WINLEVI if you develop any adrenal problems.

SAVE WITH THE WINLEVI[®] CO-PAY PROGRAM



Winlevi.

RE-ACTIVATED CO-PAY SAVINGS CAED CO-PAY SAVINGS CAED CO-PAY AS LITTLE AS CAED CO-PAY AS CO-PAY A

If you are a commercially insured patient:

 The WINLEVI Co-Pay Program can be used at any participating pharmacy

LEARN MORE about the WINLEVI Co-Pay Program and download your card now



Enrollment is subject to applicable program maximum restrictions, terms and conditions, and eligibility criteria. Please see **WINLEVI.com** for more information.

IMPORTANT PATIENT INFORMATION, CONT.

The most common side effects of WINLEVI cream

include reddening, scaling or dryness, and itching of the skin being treated.

These are not all of the possible side effects of WINLEVI cream.

Tell your healthcare provider about the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or to Sun Pharmaceutical Industries, Inc. by calling 1-800-818-4555.

Please see Full Prescribing Information and the Patient Information in the pocket or at WINLEVI.com

References: 1. Winlevi [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; September 2021. 2. US Food and Drug Administration. Novel drug approvals for 2020. https://www.fd.agov/drugs/new-drugs/fat-cdresr-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020. Updated January 13, 2021. Accessed August 2, 2022. 3. American Academy of Dermatology Association website. Acne: Who gets and causes. https://www.ado.org/updic/diseases/acne/causes/acne-causes. Accessed September 2, 2021. 4. Makrantonaki E, Ganceviciene R, Zouboulis CC. Dermatoendocrinol. 2011;3(1):41-49.
5. Del Rosso JQ, Kircik LH, Stein Gold L, et al. J Drugs Dermatol. 2020;19(3):30-35. 6. Platsidaki E, Dessinioti C, F1000Res. 2018;7:F1000 Faculty Rev-1953. Published 2018 Dec 19. doi:10.12688/ f1000research.156591. 7. Hebert A, Thiboutto D, Stein Gold L, et al. JAMA Dermatol. 2020;156(6):621-630. 8. Rosette C, Agan FJ, Mazzetti A, Moro L, Gerloni M. J Drugs Dermatol. 2019;18(5):217-223. 9. Eichenfield L, Hebert A, Gold LS, et al. JAM Acad Dermatol. 2020;83(2):477-485. 10. Mazzetti A, Moro L, Gerloni M, Cartwright M. J Drugs Dermatol. 2019;18(6):563-568.
11. Data on file. Sun Pharmaceuticals Industries, Inc.; August 2021.

